Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534174 | 0.86 | KIF11 (0.45) | KIF11CNR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL21807839 | 0.86 | KIF11 (0.45) | KIF11CNR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL4462423 | 0.73 | CNR1 (0.60) | CNR1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31248489 | 0.71 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1TSHR | |
| SCHEMBL11817100 | 0.71 | CNR1 (0.33) | CNR1KCNE1KCNQ1 | |
| SCHEMBL4611622 | 0.71 | PKM (0.41) | ALDH1A1 | |
| SCHEMBL23536157 | 0.70 | OGA (0.41) | ALDH1A1 | |
| SCHEMBL10686126 | 0.70 | HIF1A (0.45) | BRPF1ALDH1A1 | |
| SCHEMBL2666085 | 0.70 | TSHR (0.37) | ALDH1A1HSD17B10TDP1TSHR | |
| SCHEMBL7835766 | 0.69 | HIF1A (0.49) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771327-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, ABCB11 | KIF11 3723/4885CNR1 1242/4885BRPF1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.